Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

Stock Information for Avenue Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avenue Therapeutics Inc.

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.